The different stakeholders considered here are,The organization BR, its employees, management, owners etc;The investors of the organization, medical product constituent suppliers, distributors, external consultants etc;The consumers, patients who have a need for the BR product;The general society in which BR operates. Strategy 1, under utilitarianism, this strategy would appear more appropriate as many would benefit under the new technology adoption. This would be the right thing to do under rights ethics.
In strategy 2, in adapting only some changes to it and leaving of others, BR might end up gaining the most profits. Not all stakeholders benefit here. However, under utilitarianism, it does not guarantee profits to everybody. By virtue of rights, BR would not be right in adopting this strategy.
Consider stakeholder implications in the case of strategy 3. By virtue of rights, it might appear that BR has not have breached anything here. It has neither accepted a new business technology nor has gone out of the way to stop it. However, BR has breached rights to stakeholders such as investors in the company to whom BR holds a due responsibility to maximize profits. In strategy 4, BR should discuss this strategy to ensure all its investors and other stakeholders are on board and highlight that such a plan albeit costing the company in current times would be a profitable venture over time. Strategy 5 has negative implications for all stakeholders and is completely unethical under both utilitarianism and rights ethics and strategy 6 ensures that everybody profits and also is ethical under the rights theory. Strategy 7 is similar to strategy 2. However, it is not stated here that BR will only adapt elements that support profitability. Therefore, this adaptation is on an overall level better than strategy 2 when stakeholder adverse and beneficial implications are considered. If the technology is flawed in any way, then the dedicated research team that is testing it, would be helping everybody by following strategy 8.
Suggestion to manager of firm:
It is recommended that either strategy 1 or strategy 6 should be adopted, because this is the only way for BR to increase its competitive strength and also fulfill its obligations to its clients. It cannot afford to not do anything, as it would then be forfeiting its competitiveness in the market. The manager should hence ensure recommendations to the context of increasing its product competitiveness to the new technology is proposed to the board.